RPR 106972

a cocrystalline association of RPR 112808 (pristinamycin IB) and RPR 106950 (pristinamycin IIB) in a 1:2 molar ratio (45:55 by weight). Structures given in first source

Also Known As:

RPR-106972

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Streptogramins: 105
      - Virginiamycin: 84
        RPR 106972: 2
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - Streptogramins: 105
      - Virginiamycin: 84
        RPR 106972: 2

Related Diseases

Infections

10/01/1998 - "RPR 106972 demonstrates good inhibitory activity against Enterococcus faecium and may prove useful in the treatment of enterococcal infections."
07/01/1997 - "aureus ATCC 29213, 0.25 to 1 microgram/ml; and for Streptococcus pneumoniae ATCC 49619, 0.06 to 0.5 microgram/ml. The results of this study indicate that the in vitro activity of RPR 106972 against Gram-positive bacteria and selected Gram-negative respiratory organisms is promising and warrants additional studies of pharmacokinetics, and in vivo infection model dynamics."